FDA authorized belzutifan plus lenvatinib for advanced clear cell–component RCC following PD-1/PD-L1 inhibitor exposure, including progression during/after therapy or within six months of adjuvant ...
Gastric cancer remains one of the world’s most lethal malignancies, and oncologists have long struggled to explain why two ...
Yesterday, September 24, the FDA approved the combination of belzutifan (WELIREG; Merck) plus lenvatinib (LENVIMA; Eisai) to ...
Merck ( MRK) and Eisai have received U.S. FDA approval for WELIREG (belzutifan) in combination with LENVIMA (lenvatinib) for certain adults with previously treated advanced renal cell carcinoma with a ...
Proximal gastrectomy versus total gastrectomy in locally advanced upper gastric cancer after neoadjuvant chemotherapy combined with tislelizumab: The preliminary results of a multicenter, prospective, ...
Informing optimal duration of adjuvant chemotherapy (ACT) in resected stage I-IV colorectal cancer (CRC) based on early circulating tumor DNA (ctDNA) dynamics. This is an ASCO Meeting Abstract from ...
Extensive-stage small cell lung cancer remains one of the most lethal malignancies in medicine, and a new phase 2a study ...
The collaboration seeks to bring affordable cancer treatments to the region while advancing the ambitious Saudi Vision 2030.
Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved ...
Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not. In a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results